Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Brief Summary

Official Title: “Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.”

The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.

  • Study Type: Observational
  • Study Design: Observational Model: Cohort, Time Perspective: Cross-Sectional
  • Study Primary Completion Date: April 2012

Detailed Clinical Trial Description

- To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours.

- To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls.

- To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

Interventions Used in this Clinical Trial

  • Other: Blood sampling by vena punction.
    • We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.

Arms, Groups and Cohorts in this Clinical Trial

  • Group A
    • Patients with clear cell renal cell carcinoma with metastases.
  • Group B
    • Patients with low grade neuro-endocrine tumours with metastases.

Outcome Measures for this Clinical Trial

Primary Measures

  • Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.
    • Time Frame: one year
      Safety Issue?: No

Secondary Measures

  • Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.
    • Time Frame: one year
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Age 18 years old or older.
  • Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases.
  • Written informed consent

Exclusion Criteria

  • Use of L-dopa or SSRI.
  • Patients with a second primary malignancy.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • University Medical Centre Groningen
  • Provider of Information About this Clinical Study
    • Principal Investigator: S.F. Oosting, Principal Investigator – University Medical Centre Groningen
  • Overall Official(s)
    • Sjoukje F. Oosting, MD, Study Chair, University Medical Centre Groningen
    • Marloes A.M. Peters, Principal Investigator, University Medical Centre Groningen

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01398306